(RTTNews) - Organon (OGN) announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON (etonogestrel implant). NEXPLANON is ...
The U.S. Food and Drug Administration (FDA) has approved a label expansion for Nexplanon to allow its manufacturer, Organon (OGN), to market the birth control implant, indicating an efficacy duration ...
OGN received FDA approval extending NEXPLANON's contraceptive use from three years to up to five years. Trial data show no pregnancies in years four and five, showing efficacy across a wide range of ...
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results